These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32536544)

  • 1. The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis.
    Stowe J; Andrews NJ; Turner PJ; Miller E
    Vaccine; 2020 Jul; 38(32):4935-4939. PubMed ID: 32536544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children.
    Yung CF; Ma X; Cheung YB; Oh BK; Soh S; Thoon KC
    Sci Rep; 2019 Oct; 9(1):14705. PubMed ID: 31604998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal].
    De Queirós L; Castro L; Ferreira MC; Gonçalves G
    Acta Med Port; 2004; 17(1):49-53. PubMed ID: 15636727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines.
    Kamidani S; Panagiotakopoulos L; Licata C; Daley MF; Yih WK; Zerbo O; Tseng HF; DeSilva MB; Nelson JC; Groom HC; Williams JTB; Hambidge SJ; Donahue JG; Belay ED; Weintraub ES
    Pediatrics; 2022 Dec; 150(6):. PubMed ID: 36349537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.
    Baker MA; Baer B; Kulldorff M; Zichittella L; Reindel R; DeLuccia S; Lipowicz H; Freitas K; Jin R; Yih WK
    PLoS Med; 2019 Jul; 16(7):e1002844. PubMed ID: 31265459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial.
    Safadi MAP; Martinon-Torres F; Weckx LY; Moreira ED; da Fonseca Lima EJ; Willemsen A; Toneatto D; Habib MA; Borys D
    Vaccine; 2019 Aug; 37(35):4858-4863. PubMed ID: 31327652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.
    Black S; Shinefield H; Baxter R; Austrian R; Bracken L; Hansen J; Lewis E; Fireman B
    Pediatr Infect Dis J; 2004 Jun; 23(6):485-9. PubMed ID: 15194827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal and Meningococcal Vaccination among Michigan Children with Sickle Cell Disease.
    Wagner AL; Shrivastwa N; Potter RC; Lyon-Callo SK; Boulton ML
    J Pediatr; 2018 May; 196():223-229. PubMed ID: 29555094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England.
    Andrews N; Stowe J; Thomas SL; Walker JL; Miller E
    Vaccine; 2019 Aug; 37(36):5211-5217. PubMed ID: 31375437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.
    van Gils EJ; Veenhoven RH; Hak E; Rodenburg GD; Bogaert D; Ijzerman EP; Bruin JP; van Alphen L; Sanders EA
    JAMA; 2009 Jul; 302(2):159-67. PubMed ID: 19584345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants.
    Shinefield H; Black S; Ray P; Fireman B; Schwalbe J; Lewis E
    Pediatr Infect Dis J; 2002 Mar; 21(3):182-6. PubMed ID: 12005078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
    Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
    Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.